دراسة تأثير اللاتانوبروست موضعياً على ثخانة القرنية المركزية عند مرضى الزرق البدئي مفتوح الزاوية
Abstract
Purpose: To study the effect of topical Latanoprost on central corneal thickness in patients with primary open glaucoma, and to see if it would be necessary to measure central corneal thickness values regularly in those patients.
Patients and methods: This research included 19 patients who visited the ophthalmology clinic at Tishreen University Hospital and former Al-Assad University Hospital in Lattakia in the period between January 2016 and December 2016. There were 11 males and 8 females. Mean age was 56.1 + 5.08 and ages ranged between 49 and 66 years. After diagnosing glaucoma in only one eye, each patient was evaluated with an inclusive eye examination in addition to Schirmer test and measuring central corneal thickness CCT for both eyes. Latanoprost eye drop 0.005% was prescribed for the diseased eye only. Each patient was followed up after 1, 3, and 6 months.
Results: There was a significant reduction in mean CCT in the case group, from 536.52 + 17.49 microns before treatment to 529.31 + 17.82 microns after 6 months of treatment. Latanoprost was effective in reducing CCT in 79% of patients.
Conclusion: Latanoprost causes a significant reduction in central corneal thickness in patients with primary open angle glaucoma. So it is necessary to measure CCT values regularly in those patients.
الهدف: دراسة تأثير اللاتانوبروست موضعياً على ثخانة القرنية المركزية، وهل هناك ضرورة لمراقبة ثخانة القرنية المركزية بشكل دوري عند هؤلاء المرضى.
المرضى والطرائق: ضمت العينة 19 مريضاً من مراجعي العيادة العينية في مشفى تشرين الجامعي باللاذقية والأسد الجامعي سابقاً باللاذقية بين كانون الثاني 2016 وكانون الأول 2016. بلغ عدد الذكور 11 والإناث 8. العمر الوسطي 56.1 + 5.08 سنة وتراوحت الأعمار بين 49 و66 سنة. بعد تشخيص الزرق لدى المريض في عين واحدة فقط، تم التقييم بإجراء فحص عيني شامل للعينين بالإضافة لقياس ثخانة القرنية المركزية CCT واختبار شيرمر ومن ثم وصف اللاتانوبروست بشكل قطرة عينية بتركيز 0.005% للعين المصابة فقط. تمت متابعة كل مريض بفواصل شهر، 3 أشهر، و6 أشهر.
النتائج: حدث انخفاض هام في متوسط ثخانة القرنية المركزية CCT في مجموعة العيون المصابة من 17.49 + 536.52 ميكرون قبل العلاج إلى 17.82 +529.31 ميكرون بعد 6 أشهر من العلاج. وكان اللاتانوبروست فعالاً في تخفيض CCT عند 79% من المرضى.
الخلاصة: يؤدي استعمال اللاتانوبروست عند مرضى الزرق البدئي مفتوح الزاوية لانخفاض هام في ثخانة القرنية المركزية، لذلك فإنه من الضروري مراقبة قيم CCT بشكل دوري عند هؤلاء المرضى.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.